Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACP3 | P15309 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3083466 | 0.84 | CYP2C19 (0.39) | CYP2C19SRCALOX15TSHRACP3 | |
| SCHEMBL3091749 | 0.81 | LPAR2 (0.38) | CYP2C19SRCALOX15TSHRACP3 | |
| SCHEMBL3083626 | 0.80 | LPAR2 (0.41) | CYP2C19SRCALOX15TSHRACP3 | |
| SCHEMBL3080734 | 0.79 | LPAR3 (0.43) | CYP2C19SRCSMN1; SMN2ACP3 | |
| SCHEMBL3085076 | 0.79 | LPAR3 (0.43) | CYP2C19SRCSMN1; SMN2ACP3 | |
| SCHEMBL3087376 | 0.79 | LPAR3 (0.43) | CYP2C19SRCSMN1; SMN2ACP3 | |
| SCHEMBL3092713 | 0.79 | LPAR3 (0.43) | CYP2C19SRCSMN1; SMN2ACP3 | |
| SCHEMBL3096363 | 0.79 | LPAR3 (0.43) | CYP2C19SRCSMN1; SMN2ACP3 | |
| SCHEMBL759322 | 0.77 | POLB (0.46) | SRCALOX15TSHRACP3POLB | |
| SCHEMBL29025201 | 0.77 | SRC (0.44) | SRCACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150132797-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | LIFE TECHNOLOGIES CORP (US) | 2015-05-14 | — | — | US | claimed |
| US-20080038773-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | INVITROGEN CORPORATION (US) | 2008-02-14 | — | — | US | claimed |
| US-20080038772-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | INVITROGEN CORPORATION (US) | 2008-02-14 | — | — | US | claimed |
| US-20150132797-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | LIFE TECHNOLOGIES CORP (US) | 2015-05-14 | — | — | US | disclosed |
| US-20100172861-A1 | Anionic Polymers as Toxin Binders and Antibacterial Agents | GENZYME CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-7678369-B2 | Anionic polymers as toxin binders and antibacterial agents | GENZYME CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080038773-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | INVITROGEN CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080038772-A1 | COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING | INVITROGEN CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| EP-1189622-B1 | ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS | GENZYME CORP (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1800687-A2 | Anionic polymers as toxin binders and antibacterial agents | GENZYME CORPORATION (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1800686-A2 | Anionic polymers as toxin binders and antibacterial agents | GENZYME CORPORATION (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060029568-A1 | Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents | GENZYME CORPORATION (US) | 2006-02-09 | — | — | US | disclosed |
| US-6890523-B2 | Anionic polymers as toxin binders and antibacterial agents | GENZYME CORPORATION (US) | 2005-05-10 | — | — | US | disclosed |
| US-20030138397-A1 | Anionic polymers as toxin binders and antibacterial agents | GELTEX PHARMACEUTICALS, INC. | 2003-07-24 | — | — | US | disclosed |
| US-6517827-B1 | Polystyrene sulfonate polymer; Clostridium difficile | GELTEX PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| US-6517826-B1 | Polystyrene sulfonate polymer; Clostridium difficile | GELTEX PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-1189622-A2 | ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS | Geltex Pharmaceuticals, Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6290946-B1 | ADMINISTERING TO THE ANIMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A POLYMER HAVING A PLURALITY OF PENDANT ACID FUNCTIONAL GROUPS WHICH ARE DIRECTLY ATTACHED TO THE POLYMER BACKBONE OR ATTACHED TO THE POLYMER BACKBONE BY A SPACER GROUP. | GELTEX PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000069428-A2 | ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| US-4006204-A | ANTIINFLAMMATORY, PROSTAGLANDIN SYNTHETASE INHIBITORS AND RECEPTOR BLOCKERS | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100172861-A1 | Anionic Polymers as Toxin Binders and Antibacterial Agents | MSN, ANTXR2, PNKP | CYP2C19 4744/4885SRC 3822/4885PPARG 4586/4885 |
| US-20060029568-A1 | Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents | DDOST, DNPEP, IDUA | CYP2C19 4413/4885SRC 3302/4885PPARG 3714/4885 |
| US-20030138397-A1 | Anionic polymers as toxin binders and antibacterial agents | MSN, ANTXR2, PNKP | CYP2C19 4744/4885SRC 3822/4885PPARG 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.